FDA Approves Pfizer Migraine Medicine
- Share via
Pfizer Inc.’s Relpax migraine medicine won Food and Drug Administration approval, giving the world’s biggest drug maker a rival to treatments from GlaxoSmithKline, AstraZeneca and Merck & Co.
Pfizer already sells Relpax in the United Kingdom, Japan, Italy and several other nations.
The drug maker is attempting to enter a market in which GlaxoSmithKline’s Imitrex migraine medicine has annual sales of more than $1 billion, about 75% of which is in the U.S.
Shares of New York-based Pfizer fell 23 cents to $29.79 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
